





# Cardiomyopathy scaffold

---

Virginia Leombruni

# Cardiomyopathy

**HEALTHY  
HEART**



# Scaffold properties

## Materials:


polycaprolactone/chitosan/polypyrrole combined with graphene

## Biocompatibility and Biodegradability:

both chitosan and polycaprolactone


## Technique for producing the scaffold:

blend of PCPG using the electrospinning technique




# Properties


## Physical Properties




PCPG0




↑ graphene: ↓ fiber dimension  
↑ hydrophilicity



PCPG2.5




## Mechanical properties





↑ elasticity: ↑ graphene  
dry conditions

## Degradation



↑ graphene: ↑ degradation

## Hemocompatibility




PCP

PCPG


- low risk to blood clotting and thrombosis
- minimal platelet aggregation

## Cell studies




# Decellularization extracellular matrix (dECM) procedure







## Native Tissue-Derived dECM



## Cultured Cell-Derived dECM



# Ventrigel properties



Ungerleider, J. L et al (2015). Fabrication and characterization of injectable hydrogels derived from decellularized skeletal and cardiac muscle.  
Singelyn, J. M. B. et al (2009). Naturally derived myocardial matrix as an injectable scaffold for cardiac tissue engineering.

# Ventrigel - Clinical trial




VENTRIX BIO SCIENCE PRODUCT CONTACT



## KEY FEATURES

- Improves cardiac function in both subacute and chronic MI preclinical models
- Mimics the native extracellular matrix (ECM) scaffolding in the heart
- Offers a new healthy microenvironment within the myocardium to facilitate cardiac repair
- Implantable via a variety of methods including minimally-invasive cardiac catheter technology

OUR  
*Product*  
VENTRIGEL



BASELINE

✓ Safety  
✓ Feasibility

3 months

↑ 6 min walk  
↓ NYHA class  
↓ LV remodeling in the late group

6 months

# Evaluation on advantages and limitations

## Native Tissue-Derived dECM

### **Advantages:**

- Similarity to original tissue in composition and mechanical properties

### **Disadvantages:**

- Donors needed
- Higher immune response
- Pathogen transmission

## Cultured Cell-Derived dECM


### **Advantages:**

- Large scale in vitro study
- Lower immune rejection
- Easier to obtain

### **Disadvantages:**

- Poorer mechanical properties
- Challenging to prepare at a large-scale

# Requirement: mechanical properties



## 12.5% uniaxial static stretch:

- > Upregulated MYH7, CASQ2 and SERCA2
- > the alignment of collagen I, collagen III and vimentin fibrils increased


## 5% cyclic strain:

- > promote cardiac differentiation, expression of MYH6, MYH7, Cx43, and TropI


## Cyclic compression:

- > More aligned cellular morphology
- > Better preserved key cardiomyocyte markers ( $\alpha$ -actinin and n-cadherin)

# Requirement: electrical stimuli



Each current pulse was 1 ms/phase and was stimulated at 1 Hz



- > Expressions of GATA4, NKX2.5, MEF2C, and TBX5
- > Expression of cardiac contractile muscle proteins ACTC1, TNNT2, MYH7, and MYL7

**Ventrigel** - porcine cardiac dECM  
Temperature responsive  
Decrease diameter of ventricle

## Additional requirement for injectable hydrogel - lesson from the clinical trials

**AlgisyL-LVR** - Calcium-Alginate hydrogel  
2 components: Na<sup>+</sup>-Alginate and Ca<sup>2+</sup>-Alginate mix before use  
Increase wall thickness

**IK-5001** - 1% sodium alginate plus 0.3% calcium gluconate  
Ability to reversibly cross-links  
Degradable, excreted via kidney

Traverse, J. H. et al (2019). First-in-man study of a cardiac extracellular matrix hydrogel in early and late myocardial infarction patients

Anker, S. D., et al (2015). A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial).


Mann, D. L., et al (2016). One-year follow-up results from AUGMENT-HF: a multicentre randomized controlled clinical trial of the efficacy of left ventricular augmentation with AlgisyL in the treatment of heart failure.

Frey, N., et al (2014). Intracoronary delivery of injectable bioabsorbable scaffold (IK-5001) to treat left ventricular remodeling after ST-elevation myocardial infarction: a first-in-man study.

# For our scaffold: Chitosan based hydrogel

## Requirement:

- Injectable liquid
- Having parameter to activate to gel state such as: ions, pH, and temperature
- Promote regeneration of the tissue
- Biocompatibility
- Degradable
- Support mechanical and electrical properties of the tissue
- Should not trigger chronic inflammation
- Promote formation of blood vessels



## Scaffold idea:

- Biocompatibility and mechanical support: chitosan, collagen, gelatin
- Parameter activate to gel state (ex: combine with alginate activate through Calcium ion)
- Electrical properties: metal nano particles
- Formation of blood vessels: VEGF